In March 2024 Intravacc announced that it has entered a strategic partnership with Primrose Bio to enhance the development and supply of conjugate vaccines. The statement suggests that the companies will “leverage their combined experience” in the development of conjugate vaccines; Primrose Bio will supply its “industry-leading” carrier protein, PleiCRM197, for vaccine development, and Intravacc will bring “IP and know how” in vaccine conjugation and manufacturing. This will provide clients with a “seamless solution” across development and manufacturing.
“Third parties engaged in developing conjugate vaccines will have access to a seamless solution for vaccine conjugation, manufacturing, and supply.”
The partnership will harness the “synergistic strengths” of each company, “fostering innovation and efficiency in vaccine development”. Intravacc will bring “comprehensive technical expertise, state-of-the-art facilities, and robust capabilities”. This will be complemented by Primrose Bio’s “ultra-pure production, supply chain, and regulatory support” for the PeliCRM197 carrier protein. This is “vital ingredient” in conjugate vaccine formulations. It is the only commercial CRM197 used in commercial vaccines for purchase.
“The partnership signifies a strategic alignment aimed at advancing vaccine development and accessibility for researchers and industry clients.”
Dr Jan Groen, CEO of Intravacc, is “excited” to announce the partnership.
“By combining our expertise with Primrose’s cutting-edge technologies, we aim to revolutionise the landscape of conjugate vaccine development, ultimately benefiting millions worldwide.”
Dr Helge Zieler, CEO of Primrose Bio, agreed that by “expanding the capability of our PeliCRM197 franchise” through the partnership, they will create a “full-service solution” for early-stage customers and parnters needing vaccine conjugation development.
“With both companies having direct product experience in preclinical, manufacturing, and clinical development, the combined know-how of the two firms fills a gap that is needed by the vaccine industry.”
We look forward to meeting and hearing from representatives of both Intravacc and Primrose Bio at the Congress in Washington this April so do get your tickets to join us there or subscribe for more insights into the latest vaccine partnerships!
